Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.42 |
| ▸ | CDK9 | P50750 | 8/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13994152 | 0.88 | CDK9 (0.52) | BTKRETCCNT1CDK9 | |
| SCHEMBL5005411 | 0.80 | CCNT1 (0.43) | BTKCCNT1CDK9 | |
| SCHEMBL5008347 | 0.80 | BRAF (0.43) | LIMK1LIMK2CCNT1CDK9 | |
| SCHEMBL5008183 | 0.77 | MET (0.45) | LIMK1LIMK2 | |
| SCHEMBL16962516 | 0.77 | MKNK1 (0.41) | BTKCCNT1CDK9 | |
| SCHEMBL16961894 | 0.77 | CCNT1 (0.39) | BTKCCNT1CDK9 | |
| SCHEMBL5008483 | 0.76 | CCNT1 (0.47) | BTKCCNT1CDK9 | |
| SCHEMBL5004914 | 0.76 | MKNK1 (0.52) | RET | |
| SCHEMBL5005158 | 0.76 | BTK (0.43) | BTKLIMK1LIMK2CCNT1CDK9 | |
| SCHEMBL5004993 | 0.76 | LIMK1 (0.43) | RETLIMK1LIMK2CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | BTK 7/4885RET 11/4885LIMK1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.